TR201905101T4 - Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar. - Google Patents

Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar. Download PDF

Info

Publication number
TR201905101T4
TR201905101T4 TR2019/05101T TR201905101T TR201905101T4 TR 201905101 T4 TR201905101 T4 TR 201905101T4 TR 2019/05101 T TR2019/05101 T TR 2019/05101T TR 201905101 T TR201905101 T TR 201905101T TR 201905101 T4 TR201905101 T4 TR 201905101T4
Authority
TR
Turkey
Prior art keywords
tfpi
monoclonal antibodies
tissue factor
pathway inhibitor
factor pathway
Prior art date
Application number
TR2019/05101T
Other languages
English (en)
Turkish (tr)
Inventor
Wang Zhuozhi
Murphy John
Marquardt Tobias
Moosmayer Dieter
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201905101(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of TR201905101T4 publication Critical patent/TR201905101T4/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR2019/05101T 2011-04-01 2012-03-30 Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar. TR201905101T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161471101P 2011-04-01 2011-04-01

Publications (1)

Publication Number Publication Date
TR201905101T4 true TR201905101T4 (tr) 2019-05-21

Family

ID=46932389

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/05101T TR201905101T4 (tr) 2011-04-01 2012-03-30 Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar.

Country Status (37)

Country Link
US (5) US20140294832A1 (enExample)
EP (1) EP2694544B1 (enExample)
JP (4) JP6170903B2 (enExample)
KR (2) KR20190079698A (enExample)
CN (2) CN103797030B (enExample)
AU (3) AU2012236296A1 (enExample)
BR (1) BR112013025376A2 (enExample)
CA (2) CA2831907C (enExample)
CL (1) CL2013002811A1 (enExample)
CO (1) CO6890074A2 (enExample)
CR (1) CR20130499A (enExample)
CU (1) CU20130128A7 (enExample)
CY (1) CY1121538T1 (enExample)
DK (1) DK2694544T3 (enExample)
DO (1) DOP2013000218A (enExample)
EA (2) EA034214B1 (enExample)
EC (1) ECSP13012913A (enExample)
ES (1) ES2722824T3 (enExample)
GT (1) GT201300229A (enExample)
HK (1) HK1243426A1 (enExample)
HR (1) HRP20190467T1 (enExample)
HU (1) HUE042706T2 (enExample)
IL (4) IL228633B (enExample)
LT (1) LT2694544T (enExample)
MX (1) MX2013011218A (enExample)
MY (2) MY190951A (enExample)
PE (1) PE20141149A1 (enExample)
PH (4) PH12013502039B1 (enExample)
PL (1) PL2694544T3 (enExample)
PT (1) PT2694544T (enExample)
RS (1) RS58633B1 (enExample)
SG (2) SG193594A1 (enExample)
SI (1) SI2694544T1 (enExample)
TR (1) TR201905101T4 (enExample)
UA (1) UA113623C2 (enExample)
WO (1) WO2012135671A2 (enExample)
ZA (1) ZA201308169B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101792032B1 (ko) 2008-12-19 2017-11-02 백스터 인터내셔널 인코포레이티드 Tfpi 억제제 및 사용 방법
WO2010072691A1 (en) 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
DK2547355T3 (en) 2010-03-19 2017-03-20 Baxalta GmbH TFPI INHIBITORS AND METHODS OF USE
PL2694544T3 (pl) * 2011-04-01 2019-07-31 Bayer Healthcare Llc Przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
BR112014022435B1 (pt) 2012-03-21 2023-02-14 Takeda Pharmaceutical Company Limited Inibidores de tfpi e métodos de uso
US9975962B2 (en) 2012-03-30 2018-05-22 Bayer Healthcare Llc Thrombin/plasmin-regulated antibodies that bind TFPI
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US9896513B2 (en) * 2013-03-15 2018-02-20 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
EP2970497B1 (en) 2013-03-15 2017-10-25 Bayer HealthCare LLC Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics
EP3022228B1 (en) 2013-07-19 2019-02-27 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
JP6783754B2 (ja) * 2014-09-17 2020-11-11 ノヴォ ノルディスク アー/エス 組織因子経路インヒビター(1〜161)上の2つのエピトープに結合する能力がある抗体
MY178445A (en) * 2015-02-25 2020-10-13 Mogam Inst Biomedical Res Novel antibody binding to tfpi and composition comprising the same
KR102438650B1 (ko) * 2015-08-19 2022-08-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
JP7444059B2 (ja) * 2018-07-25 2024-03-06 ソニーグループ株式会社 血液凝固系解析装置
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
WO2010072691A1 (en) * 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
PT3345615T (pt) * 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
PL2694544T3 (pl) * 2011-04-01 2019-07-31 Bayer Healthcare Llc Przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations

Also Published As

Publication number Publication date
CN103797030B (zh) 2017-05-31
LT2694544T (lt) 2019-04-25
IL228633A0 (en) 2013-12-31
RS58633B1 (sr) 2019-05-31
CL2013002811A1 (es) 2014-02-28
KR20140019428A (ko) 2014-02-14
EA201991704A2 (ru) 2020-03-31
PH12019500441A1 (en) 2020-10-12
MY165499A (en) 2018-03-27
JP2021019619A (ja) 2021-02-18
PH12019500439A1 (en) 2020-10-12
HUE042706T2 (hu) 2019-07-29
IL283829A (en) 2021-07-29
CA3068997A1 (en) 2012-10-04
US20220041752A1 (en) 2022-02-10
PL2694544T3 (pl) 2019-07-31
CR20130499A (es) 2013-10-24
CA2831907A1 (en) 2012-10-04
ZA201308169B (en) 2016-03-30
AU2017203105A1 (en) 2017-06-01
JP2017113019A (ja) 2017-06-29
HK1243426A1 (zh) 2018-07-13
IL257145A (en) 2018-03-29
CA2831907C (en) 2020-03-24
CO6890074A2 (es) 2014-03-10
MX2013011218A (es) 2013-10-17
EA201991704A3 (ru) 2020-06-30
WO2012135671A2 (en) 2012-10-04
BR112013025376A2 (pt) 2017-07-25
IL274686B (en) 2021-09-30
EP2694544B1 (en) 2019-01-23
JP6363747B2 (ja) 2018-07-25
EP2694544A4 (en) 2015-03-25
CY1121538T1 (el) 2020-05-29
EA034214B1 (ru) 2020-01-17
PH12013502039A1 (en) 2013-12-16
US20140294832A1 (en) 2014-10-02
US20170107298A1 (en) 2017-04-20
GT201300229A (es) 2014-11-13
ECSP13012913A (es) 2014-02-28
IL228633B (en) 2018-03-29
AU2019201814A1 (en) 2019-04-04
ES2722824T3 (es) 2019-08-19
SI2694544T1 (sl) 2019-06-28
JP2018172411A (ja) 2018-11-08
EP2694544A2 (en) 2014-02-12
IL274686A (en) 2020-06-30
DOP2013000218A (es) 2013-11-15
KR20190079698A (ko) 2019-07-05
JP2014511685A (ja) 2014-05-19
WO2012135671A3 (en) 2012-12-13
KR101995302B1 (ko) 2019-07-02
US20180194857A1 (en) 2018-07-12
US20190194353A1 (en) 2019-06-27
AU2012236296A1 (en) 2013-10-24
SG10201602606UA (en) 2016-04-28
PH12013502039B1 (en) 2013-12-16
MY190951A (en) 2022-05-24
PH12019500440A1 (en) 2020-10-12
EA201301107A1 (ru) 2014-11-28
PE20141149A1 (es) 2014-08-28
UA113623C2 (uk) 2017-02-27
SG193594A1 (en) 2013-10-30
HRP20190467T1 (hr) 2019-05-03
CN107090046A (zh) 2017-08-25
NZ615969A (en) 2016-01-29
PT2694544T (pt) 2019-04-02
CN103797030A (zh) 2014-05-14
DK2694544T3 (en) 2019-04-15
CU20130128A7 (es) 2014-03-26
JP6170903B2 (ja) 2017-07-26

Similar Documents

Publication Publication Date Title
PH12019500441A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
EA201291034A1 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201492101A1 (ru) Антитела против fcrn
EA201791186A1 (ru) Антитела к cd38
EA201400579A1 (ru) Антитела к il-36r
UA109278C2 (uk) Лікарські засоби, які індукують апоптоз, для лікування раку і імунних і аутоімунних захворювань
UA107706C2 (uk) Апоптоз-індукуючий засіб для лікування раку й імунних і аутоімунних захворювань
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
GB201109238D0 (en) Antibodies
EA201390117A1 (ru) Композиция антител к vegfr-3